drugset / Trial / NCT00605995
Add-on Simvastatin in Schizophrenia Trial
Terminated
15 enrolled
New York State Psychiatric Institute
Merck Sharp & Dohme LLC · collabSheba Medical Center · collabStanley Medical Research Institute · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The overall purpose of this study is to determine whether the cholesterol-lowering drug simvastatin is effective in the treatment of symptoms of schizophrenia. The primary hypothesis is that patients with schizophrenia receiving add-on treatment with simvastatin will improve clinically (as measured mainly by symptom severity) compared with patients receiving placebo, and that this improvement will be accompanied by concomitant reduction in peripheral inflammatory markers.
Timeline
- Start
- 2008-02
- Primary completion
- 2011-08
- Completion
- 2011-08
Outcome
Outcome not reported
Stopped (Enrollment): “Enrollment was slower than anticipated by the investigators and the funding research foundation.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Simvastatin | Small molecule | 40 mg | Oral |